Nikolai Mühlberger, Assist.-Prof., DVM, MPH
Assist.-Prof.
Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology; Division of HTA and Bioinformatics, ONCOTYROL - Center for Personalized Cancer Medicine
Dept. Public Health, Information Systems and HTA
Eduard Wallnoefer Center I
Hall i.T./Innsbruck
Austria
6060
Papers:
2E-1
LONG-TERM EFFECTIVENESS AND COST EFFECTIVENESS OF DIFFERENT ANTIVIRAL TREATMENTS FOR CHRONIC GENOTYPE-1 HCV INFECTION IN GERMANY INCLUDING OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR
DIRECT ANTIVIRAL DRUGS FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1 OR 4 IN FRANCE - COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT DASABUVIR BY FIBROSIS SUBGROUP
THE BENEFIT-HARM BALANCE OF PROSTATE CANCER SCREENING IN MEN WITH AVERAGE AND ELEVATED FAMILIAL RISK – PREDICTIONS OF THE ONCOTYROL PROSTATE CANCER OUTCOME AND POLICY MODEL